rtki cpd and olmesartan medoxomil

rtki cpd has been researched along with olmesartan medoxomil in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Fujiyama, S; Higashiyama, S; Iba, O; Iwasaka, T; Jyo, N; Koyama, Y; Maruyama, K; Masaki, H; Matsubara, H; Mori, Y; Nose, A; Nozawa, Y; Ogata, N; Tateishi, E; Tsutsumi, Y; Uchiyama, Y	1

Other Studies

1 other study(ies) available for rtki cpd and olmesartan medoxomil

Article	Year
Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation. Circulation research, 2001, Jan-19, Volume: 88, Issue:1 Topics: Angiopoietin-1; Angiopoietin-2; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Calcium; Cells, Cultured; Cornea; Endothelial Growth Factors; Endothelium, Vascular; Enzyme Activation; Epidermal Growth Factor; ErbB Receptors; Gene Expression Regulation; Heparin-binding EGF-like Growth Factor; Imidazoles; In Vitro Techniques; Indoles; Intercellular Signaling Peptides and Proteins; Lymphokines; Maleimides; Membrane Glycoproteins; Naphthalenes; Neovascularization, Physiologic; Olmesartan Medoxomil; Protein Kinase C; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Protein Tyrosine Phosphatases; Proteins; Pyridines; Quinazolines; Rabbits; Rats; Receptor Protein-Tyrosine Kinases; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptor, TIE-2; Receptors, Angiotensin; Receptors, Cell Surface; Receptors, TIE; RNA Stability; RNA, Messenger; Tetrazoles; Time Factors; Transcriptional Activation; Tyrphostins; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors	2001

Article

Year

Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation.

Circulation research, 2001, Jan-19, Volume: 88, Issue:1

Topics: Angiopoietin-1; Angiopoietin-2; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Calcium; Cells, Cultured; Cornea; Endothelial Growth Factors; Endothelium, Vascular; Enzyme Activation; Epidermal Growth Factor; ErbB Receptors; Gene Expression Regulation; Heparin-binding EGF-like Growth Factor; Imidazoles; In Vitro Techniques; Indoles; Intercellular Signaling Peptides and Proteins; Lymphokines; Maleimides; Membrane Glycoproteins; Naphthalenes; Neovascularization, Physiologic; Olmesartan Medoxomil; Protein Kinase C; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Protein Tyrosine Phosphatases; Proteins; Pyridines; Quinazolines; Rabbits; Rats; Receptor Protein-Tyrosine Kinases; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptor, TIE-2; Receptors, Angiotensin; Receptors, Cell Surface; Receptors, TIE; RNA Stability; RNA, Messenger; Tetrazoles; Time Factors; Transcriptional Activation; Tyrphostins; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors

2001